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ABSTRACT
Objective Anaemia in rheumatoid arthritis (RA) is
prototypical of the chronic disease type and is often
neglected in clinical practice. We studied anaemia in
relation to disease activity, medications and radiographic
progression.
Methods Data were collected between 1996 and
2007 over a mean follow-up of 2.2 years. Anaemia was
deﬁned according to WHO (♀ haemoglobin<12 g/dl,
♂: haemoglobin<13 g/dl), or alternative criteria.
Anaemia prevalence was studied in relation to disease
parameters and pharmacological therapy. Radiographic
progression was analysed in 9731 radiograph sets from
2681 patients in crude longitudinal regression models
and after adjusting for potential confounding factors,
including the clinical disease activity score with the 28-
joint count for tender and swollen joints and erythrocyte
sedimentation rate (DAS28ESR) or the clinical disease
activity index (cDAI), synthetic antirheumatic drugs and
antitumour necrosis factor (TNF) therapy.
Results Anaemia prevalence decreased from more than
24% in years before 2001 to 15% in 2007. Erosions
progressed signiﬁcantly faster in patients with anaemia
(p<0.001). Adjusted models showed these effects
independently of clinical disease activity and other
indicators of disease severity. Radiographic damage
progression rates were increasing with severity of
anaemia, suggesting a ‘dose-response effect’. The effect
of anaemia on damage progression was maintained in
subgroups of patients treated with TNF blockade or
corticosteroids, and without non-selective nonsteroidal
anti-inﬂammatory drugs (NSAIDs).
Conclusions Anaemia in RA appears to capture
disease processes that remain unmeasured by established
disease activity measures in patients with or without TNF
blockade, and may help to identify patients with more
rapid erosive disease.
INTRODUCTION
Anaemia in rheumatoid arthritis (RA) is prototypical
of anaemia of chronic disease (ACD), characterised
by low serum iron concentrations in conjunction
with normal or increased storage iron.1 ACD
without functional iron deﬁciency is normochromic,
normocytic, and usually mild.2 Haemoglobin con-
centrations were a component of earlier RA disease
activity measures until they were omitted during val-
idation of the original RA disease activity score
(DAS) due to low correlation with other disease
activity measures, despite moderate correlation with
radiographic outcome.3
The signiﬁcantly higher need for joint replace-
ments and higher mortality rates in the anaemic
patients of the British early RA cohort (ERAS) chal-
lenged the concept of causal ACD treatment by
aiming at remission only with synthetic disease-
modifying antirheumatic drugs (DMARDs).4
Inhibition of human erythroid colony-forming units
in the bone marrow downstream of tumour necrosis
factor-α (TNF-α)5 and anemia6 is reversible upon
TNF-α blockade, even in otherwise refractory RA
patients. Here, we question whether anaemia in RA is
still relevant in terms of prevalence and clinical con-
sequences in the era of TNF-α blockade, one of the
most efﬁcacious and common biological RA
treatments.
METHODS
Patients and setting
This longitudinal population-based cohort study is
nested within the Swiss clinical quality management
(SCQM) database, which is described elsewhere.7
Patient registration in SCQM is restricted to board-
certiﬁed rheumatologists to follow the effectiveness
and safety of antirheumatic therapies. More than
two-thirds of all practicing rheumatologists in
Switzerland contributed patients, representing
∼10% of all hypothetical Swiss RA patients.8 9
Approximately 60% of patients come from private
practices, 20% from university hospitals, and 20%
from non-academic centres. Ethical approval for
patient enrolment into the SCQM programme and
related studies was obtained from the Swiss
Academy of Medical Sciences review board.
Written informed consent was provided by all 4377
participants with classiﬁcation criteria-guided RA
diagnosis,10 and at least one haemoglobin assess-
ment between the start of the registry in 1996 and
a major system revision in 2007.
Anaemia deﬁnitions
We used the WHO deﬁnition of anaemia with
lower normal haemoglobin limits of 12 g/dl in
women and 13 g/dl in men.11 To explore the effect
of anaemia severity, we used the less stringent
anaemia deﬁnition proposed by Beutler et al,12
using thresholds of 12.2 g/dl in white women and
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of 13.7 g/dl or 13.2 g/dl in white men aged 20–59 years, or 60
+ years, respectively, in sensitivity analyses. ‘More severe
anaemia’ was arbitrarily deﬁned (in the absence of ofﬁcial deﬁ-
nitions) by haemoglobin levels lower than 11 g/dl in women
and 12 g/dl in men. Haemoglobin concentrations, white blood
cell counts, and platelet counts were derived from certiﬁed local
laboratories.
Covariates
Registry documentation provided the American College of
Rheumatology core set of disease activity measures,13 which
allowed to calculate the DAS including the 28-joint count for
tender and swollen joints and erythrocyte sedimentation rate
(DAS28ESR)
14 and the clinical disease activity index (cDAI).15
Other covariates were age and gender, rheumatoid factor (RF)
status, and RA disease duration. RA therapies, including TNF-α
blockers, methotrexate with or without folic acid supplementa-
tion, and other synthetic DMARDs, corticosteroids,
cyclo-oxygenase-II selective (Coxib type) NSAIDs, non-
selective NSAIDs and proton-pump inhibitors (PPI). Generic
information on the presence of haematological, renal, or
gastrointestinal comorbidities was also available, without
detailed information.
Outcome
Radiographic evaluation of erosions was centrally performed by
an independent assessor following the Ratingen score, a vali-
dated method measuring quintiles of the total joint bone surface
in 38 joints in the hands and forefeet.16 Radiographic data were
expressed in percent of the maximal 190-point score and
changes over time reported in absolute differences. The minimal
detectable change for this method is ∼3.3% of the maximum
score.17
Statistical analysis
Descriptive statistics included the mean and SD for normally
distributed variables, and the median and IQR for non-
parametric continuous variables. Sporadic missing covariates
were replaced by the population mean (<5%). Between-group
differences in disease characteristics from baseline to registration
were compared using a Student t test for normally distributed
variables, the Wilcoxon rank sum test for non-normally distribu-
ted continuous variables, and Pearson’s χ2 test for dichotomous
variables. We examined potential time trends in the prevalence
and incidence of anaemia and the haemoglobin normalisation
rates with Cox regression analyses. Patients were deﬁned as
‘anaemic’ according to the chosen deﬁnition between two radio-
graphs by subnormal haemoglobin concentrations in more than
50% of determinations. We used mixed-model random-slope
regression for longitudinal data to analyse radiographic damage
progression over time. Unless otherwise stated, data were
adjusted for all baseline covariates (table 1) and the baseline and
time-varying DAS28ESR or cDAI.
14 15 Patients may have
switched between the anaemic and non-anaemic groups accord-
ing to their time-dependent haemoglobin concentration. We
chose the best-ﬁtting parsimonious covariance structure using a
series of likelihood ratio tests based on restricted maximum like-
lihood estimates. We examined whether time best ﬁt the data as
a linear trend or as a quadratic function. Finally, we selected the
best-ﬁtting mean response model of the outcome, controlling
for other covariates for the respective outcome. All statistical
tests were two-sided performed with Stata V.12 for Windows
(Stata Statistical Software, StataCorp, Texas, USA), and were
evaluated at the 0.05 signiﬁcance level.
Subgroup analyses
Subgroups were analysed in order to further address potential
treatment effects. Here, we performed statistical models for the
radiographic outcome after having selected either patients with
Table 1 Baseline patient characteristics (n=4377) according to anaemia status at inclusion
Item Anaemic (n=1054) Non-anaemic (n=3323) p Value
Age in years 55 (±15) 54 (±12) 0.08
Male gender (%) 21 23 0.17
DAS28ESR 5.2 (±1.5) 4.2 (±1.4) <0.001
cDAI 28.2 (±14.2) 21.2 (±16.3) <0.001
Disease duration in years 6.7 (6.7) 6.0 (6.4) <0.001
Erosion score (% of max) 5 (1.5–24) 3 (0.5–9) <0.001
Haemoglobin (g/dl) 11.1±1.1 13.6±1.7 <0.001
RF positivity (%) 80 76 0.03
Subcutaneous nodules (%) 31 28 0.009
Vasculitis (%) 6 4 0.005
Methotrexate (%) 41 45 0.03
Other synthetic DMARDs (%) 43 41 0.36
Anti-TNF-α agents (%) 5 6 0.26
Corticosteroids (%) 32 30 0.22
Non-selective NSAIDs (%) 34 30 0.004
Coxibs (%) 19 16 0.03
Haematological comorbidities (%) 19 4 <0.001
Renal comorbidities (%) 2 2 0.27
Gastrointestinal comorbidities (%) 9 8 0.38
Parameters with Gaussian distribution are presented by the mean±SD, and non-normally distributed parameters by median and IQR. Anti-inflammatory treatment was often intensified
after inclusion.
cDAI, clinical disease activity index15; DAS28ESR, disease activity score including the 28-joint count for tender and swollen joints and erythrocyte sedimentation rate; DMARDs,
disease-modifying antirheumatic drugs; RF, rheumatoid factor; TNF, tumour necrosis factor.
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anti-TNF-therapy (n=1020 patients) or without NSAIDs
(n=1477), which resulted in an overlap of 520 patients for both
analyses. Additional subgroup analyses were run in 1424
patients with and in 1257 subjects without corticosteroid
therapy, and in 1115 patients with successful therapy as indi-
cated by DAS28ESR deﬁned remission at ﬁnal observation.
RESULTS
Baseline characteristics of all included patients are listed in
table 1. More than 80% of subsequent consultations were
scheduled after approval of TNF-α blocking agents in
Switzerland for patients after failure of at least one conventional
DMARD. Anti-TNF-α and other DMARD therapies were often
intensiﬁed after inclusion, and the prevalence of TNF-α inhibi-
tors and second-line biologics progressively reached 35% and
2% of patients, respectively. Use of methotrexate or other con-
ventional DMARDs was registered at least once in 64% and
60% of the patients, respectively, over time.
Haemoglobin concentrations
Patients had a mean of 4.4 haemoglobin assessments over a
mean follow-up period of 2.8 years. The mean baseline haemo-
globin concentration was 12.7 (SD±1.4 g/dl) in women and
14.0±1.6 g/dl in men. Haemoglobin levels increased by 0.08
±0.04 g/dl (p=0.04) after the ﬁrst year, by 0.14±0.07 g/dl
(p=0.06) after the second year, and by 0.16±0.09 g/dl
(p=0.077) after the third year. Individual haemoglobin ﬂuctua-
tions in either direction (mean 1.6±1.2 g/dl) were more sub-
stantial. Higher haemoglobin concentrations were signiﬁcantly
associated with higher haemoglobin concentrations at baseline
(0.04, 95% CI 0.03 to 0.05, p<0.001) and male gender (1.11,
95% CI 1.03 to 1.19, p<0.001), but negatively associated with
higher DAS28ESR (−0.20 g/dl, 95% CI −0.23 to −0.18,
p<0.001), higher erosion scores (−0.005, 95% CI −0.007 to
−0.003, p<0.001), and treatment with non-selective NSAIDs
(−0.16, 95% CI −0.20 to −0.12, p<0.001), with or without
PPI cotherapy. Haemoglobin levels were not associated with
baseline renal or gastrointestinal comorbidity.
Prevalence of anaemia
Anemia11 occurred with similar frequency in men and women,
oscillating around 24%, before a continuous negative time trend
started in 2001 to reach 14.7% in 2007. No anaemia at any
visit was found in 69.2% of patients, and persistent anaemia at
all visits occurred in 10% of patients.
Incidence and correction of anaemia
The annual anaemia incidence rate was 7.6% in 2531 initially
non-anaemic patients. Patients with higher baseline DAS28ESR
(HR 1.14, 95% CI 1.07 to 1.22, p<0.001), RF positivity (HR
1.49, 95% CI 1.16 to 1.92, p=0.002), registered haemato-
logical comorbidity (HR 1.76, 95% CI 1.23 to 2.53, p=0.002)
or corticosteroid therapy (HR 1.31, 95% CI 1.03 to 1.67,
p=0.028) became signiﬁcantly more often anaemic. PPI comedi-
cation was often used in incident anaemia (HR 2.63, 95% CI
0.97 to 7.14, p=0.057) among patients with non-selective
NSAID therapy (HR 1.29, 95% CI 1.06 to 1.57, p=0.013). By
contrast, coxibs, gastrointestinal comorbidities or renal
comorbidities were not associated with different anaemia inci-
dence. Gastrointestinal toxicities were attributed to NSAIDs in
12 cases, but only one clinically manifest bleeding was reported.
Haemoglobin concentrations normalised after a median of 1.3
(IQR: 0.9–3.2) years in 800 initially anaemic patients.11
Anaemia correction was slower in patients with reported
haematological disorder (HR 0.60, 95% CI 0.48 to 0.75,
p<0.001) or under non-selective NSAIDs (HR 0.73, 95% CI
0.60 to 0.89, p=0.002), but was accelerated after anti-TNF-α
(HR 1.22, 95% CI 1.02 to 1.45, p=0.028) or PPI therapy (HR
7.77, 95% CI 1.86 to 32.39, p=0.005).
Reporting of anaemia and haematological comorbidities
Treating rheumatologists reported baseline haematological
comorbidity in only 19% of anaemic patients. Indicators of
bone marrow insufﬁciency or other relevant blood cell abnor-
malities (white blood cell count below 3 g/l and thrombocyto-
penia below 50 g/l were reported in less than 0.4% or less than
0.2% of all cases, respectively. Reactive elevations in these blood
cell counts, platelets ≥400 g/l (3.6%), or leukocytes ≥10 g/l
(13.8%) were more frequent. Patient`s treatment with iron,
vitamin B12, or erythropoietin was reported in nine, 15 and 14
cases, respectively. Malignancies were reported in 1.3% of all
patients.
Anaemia and erosions
This relationship was studied in 9731 sets of radiographs from
hands and forefeet in 2681 patients, of whom 627 individuals
were anaemic at baseline according to WHO deﬁnition. The less
stringent anaemia deﬁnition12 was fulﬁlled in 1487 individuals,
and 506 patients complied with the deﬁnition of ‘more severe
anaemia’. In crude analyses and after statistical adjustments for
potential confounding baseline parameters and the time-
dependent DAS28ESR or cDAI, anaemic patients experienced
signiﬁcantly faster radiographic progression (p<0.001) than
their non-anaemic counterparts, irrespective of the employed
anaemia deﬁnition (ﬁgure 1). A ‘dose-response effect’ was sug-
gested by the average 2.0% annual damage progression of the
maximal score in WHO-deﬁned anaemic patients versus 1.2%
in non-anaemic patients; these values were 1.4% vs 1.1%
according to the higher threshold of normal haemoglobin con-
centrations,12 but 2.4% vs 1.2% according to the deﬁnition of
‘more severe anaemia’. Signiﬁcant baseline determinants of
radiographic progression in all these statistical models were
baseline erosion scores (mean ∼1.0 in all models, p<0.001),
gender to the advantage of the male (mean 0.3–0.4%, depend-
ent on the model, p=0.024–0.038), methotrexate therapy
(mean 0.2–0.3% p=0.012–0.043), and non-selective NSAID
therapy (mean ∼0.3% in all models, p=0.013–0.024).
Subgroup analyses
We obtained similar results as in the total patient population
after exclusion of patients with non-selective NSAID therapy
(ﬁgure 2A,B). Anaemia effects on erosive progression were
reproduced in another independently selected patient popula-
tion with anti-TNF therapy (ﬁgure 2C,D). By contrast with mild
anaemia,12 WHO deﬁned11 and ‘more severe anaemia’ exhib-
ited similarly signiﬁcant effects on x-ray progression (p<0.001)
in these subgroups. Anaemia effects on radiographic outcome
went insigniﬁcant after exclusion of all patients with steroid
registration, but remained signiﬁcant in the complementary
population (p<0.001, data not shown). Finally, mean joint
damage progression was faster in anaemia after selection of
patients with DAS28ESR deﬁned remission at their last observa-
tion (p=0.026, data not shown).
DISCUSSION
In this study, WHO-deﬁned anaemia was present in approxi-
mately every ﬁfth patient at baseline, and at least in every third
patient over their observation time, demonstrating ongoing
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Figure 1 Erosive progression over time in all 2681 evaluable rheumatoid arthritis (RA) patients. Progression trajectories were adjusted for
differences in patient characteristics at their ﬁrst x-ray (table 1), (A,C) DAS including the 28-joint count for tender and swollen joints and erythrocyte
sedimentation rate (DAS28ESR) or (B,D) clinical disease activity index where indicated, plus anti-inﬂammatory therapies and covariates of RA severity.
Values are mean and 95% CI. Erosion scores progressed signiﬁcantly faster in patients with anaemia than in non-anaemic RA patients. The kinetics
of damage progression accelerated with the grade of anaemia severity. (A and C) For comparison, the lower margin of the shaded area represents
mean damage progression in clinical remission (DAS28ESR<2.6), and the upper margin disease progression in patients with high clinical disease
activity (DAS28ESR>5.1). Patient numbers at given time points are the same in left (A,C) and right hand ﬁgures (B,D).
Figure 2 Erosive progression over time was analysed in patients with and without anaemia,11 (A,B) without NSAID and (C,D) with antitumour
necrosis factor-α therapy. Values are mean and 95% CI. The progression of erosions (mean±95% CI) was adjusted for potential confounders (ﬁgure
1, table 1). Patient numbers at given time points are the same in left (A,C) and right hand ﬁgures (B,D).
4 Möller B, et al. Ann Rheum Dis 2013;0:1–6. doi:10.1136/annrheumdis-2012-202709
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relevance of anaemia despite decreasing time trends. We con-
ﬁrmed that anaemia in RA is usually mild, but still only partially
resolved by available therapeutics and of remarkable importance
for radiographic outcome.
SCQM services a typical RA registry cohort in terms of RF
status, anaemia frequency and severity,18 19 other extra-articular
RA manifestations,20 comorbidities,21 DMARD and TNF-α
blocker prescription rates.22 23 SCQM is unique among the
national registries in providing centralised radiographic assess-
ment for RA patients. The necessary compromise was the aban-
donment of the evaluation of joint space narrowing, but the
Ratingen erosion score provides good reliability and less suscep-
tibility to ceiling effects in advanced disease, since it uses a true
ordinal rating system.16
This large real-life observational study conﬁrmed that mean
joint damage progression rates are signiﬁcantly lower in clinical
remission than in active disease, but this goal was achieved at
the end of observation in only 30% of patients. Articular
inﬂammation can be detected by ultrasound and MRI in the
absence of clinically detectable inﬂammation,24 which could
explain the dissociation of disease activity from radiographic
outcome.25–27 In the present study, anaemia-related progression
of joint damage was not restricted to the patients with clinically
active disease.14 Thus, anaemia may be a useful surrogate for
subclinical RA disease activity.
The well established relationship between inﬂammation and
anaemia was conﬁrmed in this study by signiﬁcant associations
between lower haemoglobin concentrations and higher DAS28ESR
and by faster haemoglobin normalisation after TNF-α blockade.
ACD in RA may be caused by a shortened red blood cell lifespan,
pathologic iron homeostasis induced by hepcidin, and blunted
response to erythropoietin.1 Interestingly, erythropoietin treat-
ment reduced disease activity in RA patients28 29 and tissue
damage in collagen-induced arthritis models.30 Our results are
consistent with anaemia as an indicator of deﬁcient anti-
inﬂammatory properties of erythropoietin.31 Hepcidin may
trigger functional iron deﬁciency upon induction by TNF-α,
interleukin-6, and other inﬂammatory stimuli,1 resulting in
reduced intestinal iron uptake at the mucosal barrier, and iron
retention in the reticulo-endothelial system via internalisation of
the same exclusive cellular iron exporter ferroportin on both cell
types. While elevated hepcidin levels could likewise be controlled
by TNF-α blockade and manifest iron deﬁciency,32 its plasma con-
centrations appear not to be predictive for RA joint damage.33
The association between anaemia and erosions was not
observed in a smaller patient population,34 but in the large
ERAS inception cohort, anaemic patients underwent a more
aggressive course of joint destruction.2 4 The SCQM-RA cohort
includes patients with early and established disease, with lower
mean disease activity at inclusion than the ERAS cohort, and a
substantial proportion of patients received anti-TNF-α therapy,
yet the consequences of anaemia on RA outcome appear to be
similar in these two populations.3
The present study is limited by missing biological markers of
iron deﬁcient erythropoiesis, such as erythrocyte indices or
parameters of iron metabolism. Iron-deﬁciency anaemia is
increasing in industrialised countries with age and with risk
factors for bleeding,35 as seen here with an increased prevalence
and delayed recovery of anaemia in patients taking non-selective
NSAIDs, in contrast with Coxib-type NSAIDs.36 One can esti-
mate, on the basis of prevalence data in young Swiss males,15
that iron deﬁciency contributes to anaemia prevalence in about
30% of the cases before, and in 50% after, market introduction
of TNF blockers. With this assumption, the prevalence of
deﬁcient erythropoiesis may still be underestimated, as iron deﬁ-
ciency was rapidly uncovered by erythropoietin stimulation in
the vast majority of patients with longstanding and
treatment-resistant active RA.28 Here, it appears necessary to
point out that a higher proportion of similar cases with estab-
lished disease, no matter of being clinically active on a very
short term, but with subsequent functional iron deﬁciency on a
longer time perspective would not be a confounding factor, but
support the prognostic value of anaemia assessment.
Observational studies have inherent limitations, such as
incomplete data, bias by indication and confounding factors. We
do not believe there is a speciﬁc selection bias by anaemia in
this register, and the most important confounding factors have
been measured and could be adjusted for in the analysis.
Corticosteroids may carry an increased risk of anaemia due to
toxic mucosal drug effects37 or a bias by indication. As increased
rates in radiographic damage in association with anaemia were
not seen in patients without corticosteroids, this constellation
differs from that in NSAID-treated patients. Divergent reporting
of haematological conditions and true anaemic haemoglobin
levels were explainable by the mild degree in an explained
context. Missing adjustments for C-reactive protein concentra-
tions appear less critical with regard to the superior validity of
composite scores over single items.3 14 We were unable to adjust
for anticyclic citrullinated peptide antibody status as this infor-
mation was missing in 40% of patients,38 39 nor do not know
the shared epitope status in this large cohort, which may control
immune responses40 41 and determine haematopoietic progeni-
tor cell senescence.42 43
In summary, these results indicate that anaemia may serve as
predictor of worse outcome in RA patients. Our data suggest
that anaemia and erosion progression are associated independ-
ently of common disease activity outcome measures. This report
may add clinical background to recent discoveries at the nexus
of inﬂammation, haematopoiesis, and iron metabolism,30 31 and
highlights the clinical implications of anaemia in RA. Diagnosis
of anaemia in RA should prompt a thorough search for subclin-
ical disease activity, after exclusion of other frequent causes.
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